Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, Martin J. Edelman, Miguel A. Villalona‐Calero, Robert A. Kratzke, Everett E. Vokes, Vincent A. MillerJournal of Clinical Oncology 2012 · DOI

Abstract

Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. EGFR mutations identify patients most likely to benefit.
BibTeX
@article{janne2012randomized,
  author = {Pasi A. Jänne and Xiaofei Wang and Mark A. Socinski and Jeffrey Crawford and Thomas E. Stinchcombe and Lin Gu and Marzia Capelletti and Martin J. Edelman and Miguel A. Villalona‐Calero and Robert A. Kratzke and Everett E. Vokes and Vincent A. Miller},
  title = {{Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial}},
  journal = {Journal of Clinical Oncology},
  year = {2012},
  doi = {10.1200/jco.2011.40.1315},
}

Loading related content...

Figure